iF647 Anti-Human CD184 (CXCR4) Antibody
英诺赛图(InnoCyto)的 iF647 Anti-Human CD184 (CXCR4) Antibody(克隆 Ulocuplumab) 为人源 IgG4 单克隆抗体,靶向 CD184(别名 CXCR4),iF647 标记(633 nm 红色激光激发),适用于流式细胞术。提供 25 tests、100 tests 规格,目录价 ¥1,560 起,仅供科研使用(RUO)。
01产品图片

02产品简介
英诺赛图(InnoCyto)的 iF647 Anti-Human CD184 (CXCR4) Antibody(克隆 Ulocuplumab) 为人源 IgG4 单克隆抗体,靶向 CD184(别名 CXCR4),iF647 标记(633 nm 红色激光激发),适用于流式细胞术。提供 25 tests、100 tests 规格,目录价 ¥1,560 起,仅供科研使用(RUO)。
03产品介绍
规格与货号
111413 | 25 tests | ¥1,560
111414 | 100 tests | ¥4,000
119601 | 25 tests | ¥1,831
119602 | 100 tests | ¥4,271
Product Details
Regulatory Status|RUO
Protein Concentration|Supplied at a lot-specific concentration.
Storage & Handling|The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Recommended Usage|For flow cytometric staining, it is recommended to use 5 µL of this reagent per 0.5-1.0 million cells in a 100 µL volume. Optimal reagent performance should be determined by titration for each specific application. iF647 has an excitation max at 656 nm and an emission max at 670 nm.
See All Formats|Clone Ulocuplumab
Background Information
CD184, also known as CXCR4 (C-X-C chemokine receptor type 4), is a G protein-coupled receptor (GPCR) that plays a central role in cell migration, immune regulation, and development. It is expressed on a wide variety of cells, including hematopoietic stem and progenitor cells, lymphocytes, endothelial cells, and many types of cancer cells. CXCR4 primarily functions as a chemokine receptor that guides cell trafficking and positioning in response to chemotactic gradients, making it essential in immune surveillance, hematopoiesis, and organogenesis.
Structurally, CD184 is a typical seven-transmembrane GPCR composed of 352 amino acids with an extracellular N-terminal domain, seven hydrophobic transmembrane helices, three extracellular and intracellular loops, and a cytoplasmic C-terminal tail. The extracellular regions are responsible for ligand binding, while the intracellular domains interact with G proteins and β-arrestins to initiate downstream signaling cascades. The receptor is heavily glycosylated at the N-terminus, which contributes to ligand specificity and receptor stability. The cognate ligand for CD184 is CXCL12, also known as stromal cell–derived factor 1 (SDF-1). Binding of CXCL12 to CXCR4 triggers activation of multiple signaling pathways, including PI3K/AKT, MAPK/ERK, and calcium mobilization cascades, which collectively regulate migration, survival, and proliferation. The CXCL12-CXCR4 axis is critical for the homing of hematopoietic stem cells to the bone marrow and the migration of immune cells during inflammation and tissue repair.
CD184 has been implicated in numerous diseases, ranging from cancer to infectious and autoimmune disorders. In oncology, CXCR4 is frequently overexpressed in solid and hematologic malignancies, where it drives tumor growth, angiogenesis, metastasis, and resistance to therapy. The receptor also serves as a co-receptor for HIV-1 entry into T cells, enabling viral infection and progression to AIDS. Dysregulation of the CXCL12-CXCR4 axis is additionally associated with inflammatory diseases, such as rheumatoid arthritis and multiple sclerosis, due to aberrant immune cell recruitment.
Therapeutically, CXCR4 represents a major target in both cancer and regenerative medicine. Antagonists such as plerixafor (AMD3100) are used clinically to mobilize hematopoietic stem cells for transplantation. In cancer, CXCR4 inhibitors and monoclonal antibodies are under development to block metastasis and improve immunotherapy efficacy. Modulating this pathway continues to hold significant potential for controlling immune responses, enhancing stem cell therapies, and limiting disease progression across multiple clinical contexts.
Data Sheets
Human peripheral blood lymphocytes were stained with PB Anti-Human CD3 and i F647 Anti-Human CD184 (CXCR4) biosimilar Ulocuplumab (left) or an isotype control (right).
04完整参数表
参数由厂商资料整理,采购前请以最终报价单与技术协议为准。
05荣誉与资质
该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。
- 营业执照未上传
- 品牌授权未上传
- 产品检测报告未上传
- 会员身份
- 收费会员
- 经营身份
- 原厂
- 成立年份
- 2020 年
- 所在地
- 上海
- 收录条目
- 1865 个
- 平台核验
- 平台代管
06品牌与供应商
InnoCyto(上海英诺赛图生物科技有限公司)致力于通过开发高质量细胞分析试剂,加速科学发现进程。公司为研究人员提供细胞层面探索所需的工具,推动免疫学、肿瘤学等多领域的研究创新。 核心团队拥有丰富的行业经验,曾参与全球头部生命科学公司的标杆项目搭建,深刻理解工业界与学术研究的前沿需求。试剂从设计之初即以精确性、一致性、高性能为核心标准,让科学家能把精力集中在最核心的研究工作上。 公司将深厚的科学积累与对品质的严格承诺相结合,力争成为全球研究人员信赖的合作伙伴。产品线覆盖经验证的一抗与二抗、同型对照、生物类似药抗体、重组蛋白、细胞因子、免疫检测试剂盒及配套试剂,并提供重组蛋白/抗体表达与标记偶联服务。
品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。
07同类条目
同一子类内的条目才具备可比性。跨子类比较参数通常没有意义。
08同品牌其他条目
上海英诺赛图 在本目录共 1865 个条目,除本条外还有:
科研在线(TeleVM). iF647 Anti-Human CD184 (CXCR4) Antibody(119601)[EB/OL]. 产品目录, 2026-11-12. https://www.suprotek.cn/products/item/if647-anti-human-cd184-cxcr4-antibody-119601.html.
TeleVM. (2026, November 12). iF647 Anti-Human CD184 (CXCR4) Antibody(119601). 产品目录. https://www.suprotek.cn/products/item/if647-anti-human-cd184-cxcr4-antibody-119601.html
@misc{biocsp_item_if647_anti_human_cd184_cxcr4_antibody_119601,
title = {iF647 Anti-Human CD184 (CXCR4) Antibody(119601)},
author = {{科研在线}},
year = {2026},
howpublished = {产品目录},
note = {更新于 2026-11-12,产品目录},
url = {https://www.suprotek.cn/products/item/if647-anti-human-cd184-cxcr4-antibody-119601.html}
}
GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。
许可:CC BY-NC 4.0 · 转载注明来源